Cargando…
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
BACKGROUND: Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or presence of several comorbidities. We investigated whether erlotinib improves clinical outcome in these patients. METHODS: TOPICAL was a double-blind,...
Autores principales: | Lee, Siow Ming, Khan, Iftekhar, Upadhyay, Sunil, Lewanski, Conrad, Falk, Stephen, Skailes, Geraldine, Marshall, Ernie, Woll, Penella J, Hatton, Matthew, Lal, Rohit, Jones, Richard, Toy, Elizabeth, Chao, David, Middleton, Gary, Bulley, Sue, Ngai, Yenting, Rudd, Robin, Hackshaw, Allan, Boshoff, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lancet Pub. Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488187/ https://www.ncbi.nlm.nih.gov/pubmed/23078958 http://dx.doi.org/10.1016/S1470-2045(12)70412-6 |
Ejemplares similares
-
The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy()
por: Lee, Siow Ming, et al.
Publicado: (2019) -
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
por: Khan, Iftekhar, et al.
Publicado: (2015) -
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014) -
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
por: Ferry, David, et al.
Publicado: (2017) -
A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)